These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35439273)

  • 1. Cost-effectiveness of a medication event monitoring system for tuberculosis management in Morocco.
    Yang J; Kim HY; Park S; Sentissi I; Green N; Oh BK; Kim Y; Oh KH; Paek E; Park YJ; Oh IH; Lee SH
    PLoS One; 2022; 17(4):e0267292. PubMed ID: 35439273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of treating multidrug-resistant tuberculosis in treatment initiative centers and treatment follow-up centers in Ethiopia.
    Alemayehu S; Yigezu A; Hailemariam D; Hailu A
    PLoS One; 2020; 15(7):e0235820. PubMed ID: 32716915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of treating multidrug-resistant tuberculosis.
    Resch SC; Salomon JA; Murray M; Weinstein MC
    PLoS Med; 2006 Jul; 3(7):e241. PubMed ID: 16796403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
    Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
    Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medication Event Monitoring System for Infectious Tuberculosis Treatment in Morocco: A Retrospective Cohort Study.
    Park S; Sentissi I; Gil SJ; Park WS; Oh B; Son AR; Kong YJ; Park S; Paek E; Park YJ; Lee SH
    Int J Environ Res Public Health; 2019 Jan; 16(3):. PubMed ID: 30709029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of adverse drug reactions on the incremental cost-effectiveness of bedaquiline for drug-resistant tuberculosis.
    Schnippel K; Firnhaber C; Page-Shipp L; Sinanovic E
    Int J Tuberc Lung Dis; 2018 Aug; 22(8):918-925. PubMed ID: 29991402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
    Wirth D; Dass R; Hettle R
    BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drones and digital adherence monitoring for community-based tuberculosis control in remote Madagascar: A cost-effectiveness analysis.
    Bahrainwala L; Knoblauch AM; Andriamiadanarivo A; Diab MM; McKinney J; Small PM; Kahn JG; Fair E; Rakotosamimanana N; Grandjean Lapierre S
    PLoS One; 2020; 15(7):e0235572. PubMed ID: 32634140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa.
    Mpobela Agnarson A; Williams A; Kambili C; Mattson G; Metz L
    Expert Rev Anti Infect Ther; 2020 May; 18(5):475-483. PubMed ID: 32186925
    [No Abstract]   [Full Text] [Related]  

  • 10. Modeling the patient and health system impacts of alternative xpert® MTB/RIF algorithms for the diagnosis of pulmonary tuberculosis in Addis Ababa, Ethiopia.
    Tesfaye A; Fiseha D; Assefa D; Klinkenberg E; Balanco S; Langley I
    BMC Infect Dis; 2017 May; 17(1):318. PubMed ID: 28464797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of treating multi-drug resistant tuberculosis by adding Deltyba™ to background regimens in Germany.
    Diel R; Hittel N; Schaberg T
    Respir Med; 2015 May; 109(5):632-41. PubMed ID: 25862597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria.
    Bada FO; Blok N; Okpokoro E; Dutt S; Akolo C; Dakum P; Abimiku A
    PLoS One; 2020; 15(12):e0241065. PubMed ID: 33259492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing adherence to MDR-TB treatment among patients on self-administered therapy and those on directly observed therapy: non-inferiority randomized controlled trial.
    Wekesa C; Sekaggya-Wiltshire C; Muyanja SZ; Lume I; Nabaggala MS; Parkes-Ratanshi R; Akello SA
    Trials; 2023 May; 24(1):326. PubMed ID: 37173761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of decentralised care model for managing MDR-TB in India.
    John D; Chatterjee P; Murthy S; Bhat R; Musa BM
    Indian J Tuberc; 2018 Jul; 65(3):208-217. PubMed ID: 29933862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis.
    Fitzpatrick C; Floyd K
    Pharmacoeconomics; 2012 Jan; 30(1):63-80. PubMed ID: 22070215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microscopic observation drug-susceptibility assay vs. Xpert
    Wikman-Jorgensen PE; Llenas-García J; Pérez-Porcuna TM; Hobbins M; Ehmer J; Mussa MA; Ascaso C
    Trop Med Int Health; 2017 Jun; 22(6):734-743. PubMed ID: 28380276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia.
    Floyd K; Hutubessy R; Kliiman K; Centis R; Khurieva N; Jakobowiak W; Danilovits M; Peremitin G; Keshavjee S; Migliori GB
    Eur Respir J; 2012 Jul; 40(1):133-42. PubMed ID: 22362862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review.
    Laurence YV; Griffiths UK; Vassall A
    Pharmacoeconomics; 2015 Sep; 33(9):939-55. PubMed ID: 25939501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis.
    Marks SM; Mase SR; Morris SB
    Clin Infect Dis; 2017 Jun; 64(12):1670-1677. PubMed ID: 28329197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries.
    Lu X; Smare C; Kambili C; El Khoury AC; Wolfson LJ
    BMC Health Serv Res; 2017 Jan; 17(1):87. PubMed ID: 28122562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.